Medigen Biotechnology Cash Flow-to-Debt Ratio
Medigen Biotechnology cash flow-to-debt ratio. Medigen Biotechnology (3176) has a Cash Flow-to-Debt Ratio of -0.01x as of September 2025, meaning its operating cash flow of NT$-18.91 Million could theoretically repay 0% of its total liabilities (NT$1.45 Billion) in one year. Check 3176 operating cash flow to net income to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Medigen Biotechnology (2003–2024)
Cash flow-to-debt ratio of Medigen Biotechnology from 2003 to 2024. Historical debt coverage capacity for Medigen Biotechnology across 12 annual periods. Check Medigen Biotechnology total reinvestment intensity to assess the company's total reinvestment commitment from operating cash flow.
Medigen Biotechnology Cash Flow-to-Debt Ratio by Year (2003–2024)
Medigen Biotechnology cash flow-to-debt ratio by year from 2003 to 2024. Year-by-year debt coverage analysis for Medigen Biotechnology. For the full cash flow conversion analysis, see how efficiently does Medigen Biotechnology generate cash.
| Year | CF-to-Debt Ratio | Operating CF (TWD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | 0.02x | NT$37.92 Million | NT$1.67 Billion | ▲ +114.1% |
| 2023 | -0.16x | NT$-569.40 Million | NT$3.53 Billion | ▲ +49.8% |
| 2022 | -0.32x | NT$-1.13 Billion | NT$3.51 Billion | ▼ -210.1% |
| 2021 | 0.29x | NT$517.45 Million | NT$1.77 Billion | ▲ +171.8% |
| 2020 | -0.41x | NT$-671.38 Million | NT$1.65 Billion | ▼ -55.4% |
| 2019 | -0.26x | NT$-560.17 Million | NT$2.14 Billion | ▲ +18.3% |
| 2018 | -0.32x | NT$-529.82 Million | NT$1.66 Billion | ▼ -18.6% |
| 2017 | -0.27x | NT$-455.62 Million | NT$1.69 Billion | ▲ +26.1% |
| 2016 | -0.36x | NT$-468.61 Million | NT$1.28 Billion | ▼ -227.8% |
| 2015 | 0.29x | NT$294.18 Million | NT$1.03 Billion | ▼ -81.7% |
| 2005 | 1.56x | NT$80.72 Million | NT$51.78 Million | ▼ -61.5% |
| 2003 | 4.04x | NT$445.46 Million | NT$110.16 Million | — |